Use of reboxetine in bulimia nervosa: a pilot study

Journal of Psychopharmacology
Secondo FassinoAndrea Pierò

Abstract

The pharmacological approach to bulimia nervosa is mainly based (BN) on selective serotonin reuptake inhibitors, but many elements suggest the possible involvement of the noradrenergic system in this disorder. The aim of the study was to assess the efficacy of reboxetine--a selective norepinephrine uptake inhibitor--in a sample of bulimic outpatients, after 3 months of treatment. Twenty-eight of 77 consecutively admitted patients with a DSM-IV diagnosis of BN (without Axis I comorbidity) received reboxetine. All patients were assessed at baseline (T0), and after 1 month (T1) and 3 months (T3), respectively, of treatment with reboxetine 4 mg/day. The subjects were administered the following questionnaires: Hamilton Rating Scale for Anxiety (HAM-A) and for Depression (HAM-D), Global Assessment Functioning (GAF), Eating Disorder Inventory-2 (EDI-2) and Body Shape Questionnaire (BSQ). Sixty percent of the patients were responsive to treatment(evaluated as a 50% decrease of bulimic behaviours). After 3 months of treatment, a significant reduction emerged in the scores of various EDI-2 subscales (Bulimia, Drive for Thinness, Body Dissatisfaction, Social Insecurity, Interpersonal Distrust, etc.) and in the BSQ total score. Moreover, d...Continue Reading

References

Jan 1, 1992·The American Journal of Psychiatry·W S AgrasL M Koran
Jan 1, 1990·The American Journal of Clinical Hypnosis·G Groth-Marnat, J F Schumaker
Jan 1, 1995·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·M R First
Nov 1, 1997·The International Journal of Eating Disorders·J E MitchellS Crow
Apr 20, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S A Montgomery
Jan 5, 2000·The American Journal of Psychiatry·D A Lewis
Mar 23, 2000·Eating and Weight Disorders : EWD·C CalandraA Giuffrida
May 9, 2000·The International Journal of Eating Disorders·J E MitchellB T Walsh
Jul 27, 2000·The American Journal of Psychiatry·B T WalshM K Chally
Oct 31, 2000·Nutrition·P J Wellman
Dec 8, 2000·International Clinical Psychopharmacology·N El-GiamalS Kasper
Apr 4, 2001·The International Journal of Eating Disorders·G K FrankM D Marcus
Jun 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·C BizeulD Rigaud
Dec 26, 2001·Journal of Psychosomatic Research·S FassinoG G Rovera
May 4, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·April J Zhu, B Timothy Walsh
Aug 3, 2002·The American Journal of Psychiatry·Hans-Christoph Steinhausen
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Secondo FassinoGiovanni Rovera
Mar 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nadia El-GiamalSiegfried Kasper
Jul 23, 2003·Journal of Psychopharmacology·Wai S Tse, Alyson J Bond
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON

❮ Previous
Next ❯

Citations

Aug 30, 2008·Neuropsychiatric Disease and Treatment·Shun'ichi NomaTakuji Hayashi
Jul 1, 2005·Women's Health·James E MitchellJames Roerig
Apr 26, 2006·Expert Opinion on Emerging Drugs·Kristine J SteffenSaritha Uppala
Feb 15, 2011·Diabetes & Metabolism·D RigaudB Vergès
Jul 5, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Paolo LeombruniSecondo Fassino
Jul 27, 2005·British Journal of Clinical Pharmacology·T Y-T LuA A Mangoni
Dec 2, 2008·The International Journal of Eating Disorders·Iris Podar, Jüri Allik
Sep 24, 2014·The Pharmacogenomics Journal·C Gamero-VillarroelG Gervasini
Jul 3, 2013·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Rigaud DanielPennacchio Hélène
Mar 29, 2011·The International Journal of Neuropsychopharmacology·Phillipa J Hay, Angélica M Claudino
Apr 30, 2011·JPEN. Journal of Parenteral and Enteral Nutrition·Daniel Jacques RigaudBruno Vergès
Jan 13, 2006·Journal of Psychopharmacology·Eric Hazen, Maurizio Fava
Apr 21, 2006·Human Psychopharmacology·Paolo LeombruniSecondo Fassino
Nov 3, 2006·The International Journal of Eating Disorders·James E MitchellStephen Wonderlich
Dec 14, 2018·CNS Drugs·Susan L McElroyFrancisco Romo-Nava

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.